Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited (TLX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tlx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Telix Pharmaceuticals Limited (TLX) measures how much investors pay for each dollar of the company's trailing earnings. TLX's current PE ratio of N/A is calculated by dividing its stock price of $9.31 by its TTM earnings per share of -$0.03.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
1999 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Telix Pharmaceuticals LimitedYou TLX | $3.2B | N/A | — | -$0.03 |
 ACADIA Pharmaceuticals Inc. ACAD | $3.7B | 11.57x | -50.8% | $2.31 |
 ADMA Biologics, Inc. ADMA | $1.9B | 29.58x | +25.8% | $0.62 |
 Belite Bio, Inc BLTE | $5.6B | N/A | — | -$2.31 |
 Celcuity Inc. CELC | $4.3B | N/A | — | -$3.37 |
 Dyne Therapeutics, Inc. DYN | $2.8B | N/A | — | -$3.47 |
 Ligand Pharmaceuticals Incorporated LGND | $4.8B | 29.38x | +25.0% | $6.44 |
Industry Average 3 peers with valid PE | — | 23.51x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.03 | — | |
2024-12-31 FY2024 | 165.07x | $0.15 | -87.9% | |
2023-12-31 FY2023 | 1361.87x | $0.02 | — | |
2022-12-31 FY2022 | — | $-0.34 | — | |
2021-12-31 FY2021 | — | $-0.29 | — | |
2020-12-31 FY2020 | — | $-0.17 | — | |
2019-12-31 FY2019 | — | $-0.12 | — | |
2018-12-31 FY2018 | — | $-0.07 | — | |
2017-12-31 FY2017 | — | $-0.05 | — | |
2016-12-31 FY2016 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Telix Pharmaceuticals Limited (TLX) measures how much investors pay for each dollar of the company's trailing earnings. TLX's current PE ratio of N/A is calculated by dividing its stock price of $9.31 by its TTM earnings per share of -$0.03.
Frequently asked questions
TLX pe ratio · 6 questionsTLX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $9.31 and TTM EPS of -$0.03. Data sourced from Financial Modeling Prep via TLX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Telix Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08